Stock analysts at Redburn Partners initiated coverage on shares of QIAGEN (NYSE:QGEN) in a report issued on wednesday. The brokerage set a Buy rating on the Medical stock. A price-to-earnings ratio of 25.3 and a beta of 0.26. QIAGEN has a twelve month low $45.33 of and a twelve month high of $59.00.
Shares of QIAGEN traded up $0.71 on wednesday, reaching $52.04. 37624 shares of the stock traded hands, compared to its average volume of 688314. Shares of QIAGEN were trading at $52.04 on wednesday. The firm’s 50 day moving average is $$53.27 and its 200 day moving average is $51.03.QIAGEN has a 12 month low of $51.53 and a 12 month high of $59.00. While on yearly highs and lows, QIAGEN’s today has traded high as $52.06 and has touched $51.53 on the downward trend. See More Analyst Rating at: RATING
QIAGEN Earnings and What to expect:
QIAGEN last issued its quarterly earnings results on July 29th, 2021. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.01. The company had revenue of $567.31 million for the quarter, compared to analyst estimates of $562.35 million. QIAGEN has generated $2.15 earnings per share over the last year ($2.06 diluted earnings per share) and currently has a price-to-earnings ratio of 24.9. Earnings for QIAGEN are expected to decrease by -17.14% in the coming year, from $2.45 to $2.03 per share. QIAGEN has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, October 26th, 2021 based off prior year’s report dates.
Earnings for QIAGEN are expected to decrease by -17.14% in the coming year, from $2.45 to $2.03 per share. The P/E ratio of QIAGEN is 24.90, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.32. The P/E ratio of QIAGEN is 24.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.56. QIAGEN has a PEG Ratio of 1.98. PEG Ratios above 1 indicate that a company could be overvalued. QIAGEN has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
QIAGEN (NYSE:QGEN) Moving Average Technical Analysis
5 day Moving Average is $51.23 And 5 day price change is $0.77 (1.51%) with average volume for 5 day average is 300,092. While technical analysis for average 20 days shows significant difference, 20 day moving average is $52.29 and 20 day price change is -$2.26 (-4.17%) and average 20 day moving volume is 682,553. 50 day moving average is $53.27 and 50 day price change is -$0.83 ( -1.57%) and with average volume for 50 days is : 650,435. 200 day moving average is $51.03 and 200 day price change is -$0.77 (-1.46%) and with average volume for 200 days is : 770,464.
Other owners latest trading in QIAGEN :
- On 10/8/2021 shares held by Veriti Management LLC were 4,909 which equates to market value of $0.25M and appx 0.00% owners of QIAGEN
- On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 790,200 which equates to market value of $38.23M and appx 0.00% owners of QIAGEN
- On 8/26/2021 shares held by Y Intercept Hong Kong Ltd were 8,717 which equates to market value of $0.42M and appx 0.10% owners of QIAGEN
- In total Institutional ownership equates to Institutional Ownership Percentage: 52.17% for QIAGEN
See More Analyst Rating at: RATING